Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation (Nasdaq: OPRX) regularly issues news and updates about its healthcare technology platform, partnerships, and financial performance. Company press releases describe OptimizeRx as a healthcare technology company that helps life science brands reach and engage healthcare professionals (HCPs) and patients through AI-driven tools, point-of-care integrations, and proprietary audience data.
News items for OptimizeRx often cover collaborations with other data and media companies, such as integrations that connect its patented Micro-Neighborhood® audience data with external identity graphs or out-of-home advertising networks. These announcements explain how the company’s privacy-safe, deterministic audience cohorts are used to support omnichannel and direct-to-consumer campaigns, improve audience quality, and reduce audience loss during onboarding and activation.
Investors and observers will also find earnings releases and guidance updates among OptimizeRx news. These releases include discussions of revenue trends, profitability metrics, key performance indicators related to top pharmaceutical manufacturers, and commentary from management about the company’s progress toward its strategic objectives. Conference call announcements and investor conference participation are also common topics, providing details on how to access management’s discussions of quarterly and annual results.
Additional news highlights may include expansions of the company’s in-workflow point-of-care network through new or renewed agreements with electronic health record (EHR) vendors, e-prescribing platforms, and health systems access partners. Leadership updates and organizational changes are reported through current reports and associated press releases, outlining adjustments in executive roles and governance. For anyone following OPRX, this news page serves as a central source for official company communications on partnerships, technology developments, financial results, and corporate governance.
OptimizeRx Corp (Nasdaq: OPRX) reported preliminary financial results for Q4 2021, anticipating revenues of approximately $20.3 million, marking a 42% increase year-over-year. The company achieved a GAAP net income of $0.6 million and a record adjusted EBITDA of $4.0 million. As part of its growth strategy, OptimizeRx introduced new KPIs focused on customer penetration within the top pharmaceutical manufacturers and aims for 2022 revenues between $80 million to $85 million, projecting 31% to 39% growth.
OptimizeRx Corp. (Nasdaq: OPRX) will conduct a conference call on February 24, 2022, at 4:30 p.m. ET to discuss its fourth-quarter and full-year financial results for 2021. The call will include a Q&A session following the management's presentation. Interested parties can access the conference via toll-free and international numbers or through a webcast link. A replay will be available for 12 months on the OptimizeRx investor website. The Company focuses on digital health solutions, connecting over 60% of U.S. healthcare providers and millions of patients.
OptimizeRx Corp (Nasdaq: OPRX) announced that CEO Will Febbo will participate in Bank of America's Annual HCIT and Digital Health Conference on February 23, 2022. He will speak on a panel titled 'Tech-Enabled Rx Solutions' from 11:15 AM ET to 12:00 PM ET. The event will attract healthcare executives and investors focused on digital health and technology solutions.
OptimizeRx is a leader in point-of-care technology, connecting over 60% of U.S. healthcare providers and millions of patients to improve therapy adherence.
OptimizeRx Corp (Nasdaq: OPRX) announced that vice president of data product, Mike Rousselle, has been named to MM+M’s 40 Under 40 List, highlighting his significant contributions to healthcare marketing. Rousselle is known for leveraging AI and ML to enhance patient-physician communication through the utilization of real-world data. This recognition not only reflects Rousselle's innovative leadership but also reinforces OptimizeRx's commitment to improving patient outcomes by connecting life sciences organizations with healthcare providers effectively.
OptimizeRx Corp (Nasdaq: OPRX), a leading health technology provider, announced participation in two key conferences: the 11th Annual SVB Leerink Global Healthcare Conference on February 17 and the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15. Will Febbo, CEO, will feature in a fireside chat at the SVB event, while the company will present at the BTIG conference. The leadership team will also be available for virtual one-on-one meetings to discuss their innovative point-of-care technology solutions.
Summary not available.
OptimizeRx Corp (Nasdaq: OPRX) announced its CEO, Will Febbo, will moderate a panel on 'Telehealth & Digital Medicine: At a Crossroads of Virtual Care' at the LifeSci Partners Corporate Access Event from January 5-7, 2022. The panel will occur on January 6, 2022, at 8:30 AM ET. Other companies participating include Augmedix, DarioHealth, and LifeMD. Interested viewers must register in advance to access the panel. OptimizeRx's technology solutions aim to help patients start and stay on therapy, connecting over 60% of U.S. healthcare providers.
OptimizeRx Corp (Nasdaq: OPRX) announced that its Evidence-Based Physician Engagement solution has been recognized as one of the most innovative products of the year in life sciences by PM360. The solution utilizes AI-driven technology to assist healthcare providers with real-time insights, aiding in identifying patients needing specific therapies and improving adherence. The platform has seen early success with several enterprise clients onboarded, indicating a growing demand for technology that enhances patient outcomes. This recognition underscores the company's role in innovating healthcare delivery.
OptimizeRx Corp. (Nasdaq: OPRX) has announced internal management changes aimed at strengthening its operational and financial strategy. CEO Will Febbo highlighted a 45% compounded annual growth rate over the past three years and a market cap nearing $1 billion. Ed Stelmakh has joined as CFO and COO, focusing on key performance indicators and scaling operations. Miriam Paramore will transition to an advisory role, having successfully transitioned her responsibilities. The leadership team aims to leverage technology for improved patient health outcomes in the growing digital healthcare market.
Summary not available.